Please login to the form below

Not currently logged in
Email:
Password:

cancer drug pricing

This page shows the latest cancer drug pricing news and features for those working in and with pharma, biotech and healthcare.

EU starts investigation of Aspen's cancer drug pricing

EU starts investigation of Aspen's cancer drug pricing

Amid reports of price increases of several hundred per cent. Aspen Pharmacare is under investigation by the EU's competition authorities over its pricing of five cancer medicines, amid allegations of ... possible price-fixing among generic medicine drugs

Latest news

  • NICE U-turn on Opdivo for kidney cancer NICE U-turn on Opdivo for kidney cancer

    happy that NICE has made this recommendation for patients with advanced kidney cancer and their families.”. ... Nick Turkentine, chief executive of Kidney Cancer UK, said: “Today's landmark decision is hugely welcome news for kidney cancer patients

  • Italian pharma scandals prompts call for EU-wide pricing probe Italian pharma scandals prompts call for EU-wide pricing probe

    Aspen fined 5.2m for threat to halt supply of cancer drugs if price hikes not accepted. ... a possible link between drug shortages and inflated pricing.

  • NICE turns down Keytruda for lung cancer in draft guidance NICE turns down Keytruda for lung cancer in draft guidance

    Says long-term benefits for advanced non-small cell lung cancer treatment not proven. ... NICE has been taking an increasingly tough stance on cancer drug pricing, holding out for steep discounts in order to reduce the NHS' spending on medicines.

  • NICE backs five new drugs after discounts agreed NICE backs five new drugs after discounts agreed

    The UK drug-prescribing watchdog has backed the funding of five new drugs for cancer, high cholesterol and a chronic and debilitating skin disease. ... NICE had previously recommended the use of Tafinlar in melanoma in 2014 - before GlaxoSmithKline (GSK)

  • Tension expected as cancer market rises to $150bn-plus Tension expected as cancer market rises to $150bn-plus

    Last year, cancer drug sales were $107bn, an 11.5% increase on the $90bn recorded in the prior year, says the report, which has been published just as the American Society ... Debate on cancer drug pricing is expected to feature prominently alongside

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....